Onderzoeker
Marc BUYSE
- Trefwoorden:Wiskunde
- Disciplines:Andere wiskunde en statistiek niet elders geclassificeerd
Affiliaties
- Data Science Instituut (Onderzoeksinstituut)
Lid
Vanaf1 jun 2019 → Heden - Wiskunde en statistiek (Departement)
Lid
Vanaf1 jan 2013 → Heden - Centrum voor Statistiek (Onderzoeksgroep)
Lid
Vanaf1 jan 1994 → Heden - Wetenschappen (Faculteit)
Lid
Vanaf1 okt 1991 → Heden - Toegepaste wiskunde (Departement)
Lid
Vanaf1 okt 2001 → 31 dec 2012 - Centrum voor Statistiek (Onderzoeksinstituut)
Lid
Vanaf1 okt 1994 → 31 mei 2019 - Wiskunde, natuurkunde, informatica (Afdeling)
Lid
Vanaf1 okt 1991 → 30 sep 2009
Publicaties
31 - 40 van 109
- Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country(2020)
Auteurs: Geert MOLENBERGHS, Marc BUYSE, Steven ABRAMS, Niel HENS, Philippe Beutels, Christel FAES, Geert VERBEKE, Pierre Van Damme, Herman Goossens, Thomas NEYENS, et al.
- Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints(2020)
Auteurs: Everardo D. Saad, Marc BUYSE
Pagina's: 384 - 390 - Outcome measures in multimodal rectal cancer trials(2020)
Auteurs: Emmanouil Fokas, Robert Glynne-Jones, Ane Appelt, Regina Beets-Tan, Geerard Beets, Karin Haustermans, Corrie Marijnen, Bruce D. Minsky, Ethan Ludmir, Phil Quirke, et al.
Pagina's: E252 - E264 - Commentary on Bamat et al(2020)
Auteurs: Everardo D. Saad, Marc BUYSE
Pagina's: 560 - 561 - Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring(2019)
Auteurs: Laura Trotta, Yuusuke Kabeya, Marc BUYSE, Erik Doffagne, David Venet, Lieven Desmet, Tomasz BURZYKOWSKI, Akira Tsuburaya, Kazuhiro Yoshida, Yumi Miyashita, et al.
Pagina's: 512 - 522 - Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis(2019)
Auteurs: Everardo D. Saad, Pierre Squifflet, Tomasz BURZYKOWSKI, Emmanuel Quinaux, Suzette Delaloge, Dimitris Mavroudis, Edith Perez, Martine Piccart-Gebhart, Bryan P. Schneider, Dennis Slamon, et al.
Pagina's: 361 - 370 - Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC(2019)
Auteurs: Jacek Rutkowski, Everardo D. Saad, Tomasz BURZYKOWSKI, Marc BUYSE, Jacek Jassem
Pagina's: 1619 - 1627 - A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses(2019)
Auteurs: Federico Rotolo, Xavier PAOLETTI, Tomasz BURZYKOWSKI, Marc BUYSE, Stefan Michiels
Pagina's: 170 - 183 - Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit(2019)
Auteurs: Julien Peron, Alexandre Lambert, Stephane Munier, Brice Ozenne, Joris Giai, Pascal Roy, Stephane Dalle, Abigirl Machingura, Delphine Maucort-Boulch, Marc BUYSE
Pagina's: 1186 - 1191 - Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer(2019)
Auteurs: Tomasz BURZYKOWSKI, E. Coart, E.D. Saad, Q. Shi, D.W. Sommeijer, C. Bokemeyer, E. Díaz-Rubio, Jean-Yves Douillard, A. Falcone, C. Fuchs, et al.